INQOVI

Peak

cedazuridine and decitabine

Taiho Oncology
NDAORALTABLETPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

Nucleic Acid Synthesis Inhibitors

Pharmacologic Class:

Nucleoside Metabolic Inhibitor

Clinical Trials (1)

NCT04980404Phase 1Active Not Recruiting

Inqovi Maintenance Therapy in Myeloid Neoplasms

Started Sep 2021

Loss of Exclusivity

LOE Date
Feb 24, 2041
182 months away
Patent Expiry
Feb 24, 2041
Exclusivity Expiry
Jul 7, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
8618075
Oct 16, 2028
U-2867
9567363
Oct 16, 2028
Substance
—
8268800
Aug 22, 2030
Substance
U-2867
12195496
Oct 7, 2040
Product
—
11963971
Feb 24, 2041
Product
—
Company
Taiho Oncology
Taiho Oncology
NJ - Princeton
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers